Details for Patent: 8,445,507
✉ Email this page to a colleague
Which drugs does patent 8,445,507 protect, and when does it expire?
Patent 8,445,507 protects ERLEADA and is included in one NDA.
This patent has eighty-three patent family members in nineteen countries.
Summary for Patent: 8,445,507
| Title: | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| Abstract: | A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders. |
| Inventor(s): | Jung; Michael E. (Los Angeles, CA), Sawyers; Charles L. (New York, NY), Ouk; Samedy (Los Angeles, CA), Tran; Chris (New York, NY), Wongvipat; John (New York, NY) |
| Assignee: | The Regents of the University of California (Oakland, CA) |
| Application Number: | 12/294,881 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,445,507 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; Delivery; Dosage form; |
Drugs Protected by US Patent 8,445,507
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-001 | Feb 14, 2018 | RX | Yes | No | 8,445,507 | ⤷ Subscribe | Y | Y | TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC) | ⤷ Subscribe | ||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-001 | Feb 14, 2018 | RX | Yes | No | 8,445,507 | ⤷ Subscribe | Y | Y | TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC) | ⤷ Subscribe | ||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-002 | Feb 17, 2023 | RX | Yes | Yes | 8,445,507 | ⤷ Subscribe | Y | Y | TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC) | ⤷ Subscribe | ||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-002 | Feb 17, 2023 | RX | Yes | Yes | 8,445,507 | ⤷ Subscribe | Y | Y | TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC) | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,445,507
| PCT Information | |||
| PCT Filed | March 27, 2007 | PCT Application Number: | PCT/US2007/007485 |
| PCT Publication Date: | November 08, 2007 | PCT Publication Number: | WO2007/126765 |
International Family Members for US Patent 8,445,507
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2368550 | ⤷ Subscribe | 300993 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2368550 | ⤷ Subscribe | CA 2019 00029 | Denmark | ⤷ Subscribe |
| European Patent Office | 2368550 | ⤷ Subscribe | 2019C/529 | Belgium | ⤷ Subscribe |
| European Patent Office | 2368550 | ⤷ Subscribe | 122019000060 | Germany | ⤷ Subscribe |
| European Patent Office | 2368550 | ⤷ Subscribe | LUC00123 | Luxembourg | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
